Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter McLaughlin

Showing results (11-20 of 116) with videos related to

Pageof 12
Sort By:
Leukemia & Lymphoma|April 25, 2007
Angioimmunoblastic T-cell lymphoma: still a dismal prognosis with current treatment approachesBarbara Pro, Peter McLaughlin
Leukemia & Lymphoma|October 30, 2009
De novo CD5+ diffuse large B-cell lymphoma: a distinct subset with adverse features, poor failure-free survival and outcome with conventional therapyJason Westin, Peter McLaughlin
Leukemia & Lymphoma|October 30, 2009
Interferon: does it still have a role in the 21st century?Peter McLaughlin, Stefano Sacchi
Leukemia & Lymphoma|March 29, 2011
The pharmacokinetic fate of an immunotoxin: HAMA, HARA, ding, ding, dongMichael Rosenblum, Peter McLaughlin
Leukemia & Lymphoma|February 24, 2009
Seeking wisdom from the SeerPeter McLaughlin, Jonathan W Friedberg
Cardiology Clinics|October 10, 2002
How congenital heart disease originates in fetal lifeRuth Collins-Nakai, Peter McLaughlin
Leukemia & Lymphoma|September 24, 2015
Stage I-II follicular lymphoma: an endangered species?Peter McLaughlin, John F Seymour
Leukemia & Lymphoma|May 3, 2008
R-DHAP: a good small step, but not the journey's endPeter McLaughlin, Julie M Vose
Cardiology Clinics|November 14, 2006
The role of cardiac catheterization in adult congenital heart diseasePeter McLaughlin, Lee Benson, Eric Horlick
Leukemia & Lymphoma|August 3, 2013
Chemoimmunotherapy with fludarabine, cytoxan and rituximab regimen: to use, not to use, or give it as "FCR-LITE"?Tamar Tadmor, Peter McLaughlin, Aaron Polliack
Pageof 12

Showing results (11-20 of 116) with videos related to

Sort By:
Pageof 12
Leukemia & Lymphoma|April 25, 2007
Angioimmunoblastic T-cell lymphoma: still a dismal prognosis with current treatment approachesBarbara Pro, Peter McLaughlin
Leukemia & Lymphoma|October 30, 2009
De novo CD5+ diffuse large B-cell lymphoma: a distinct subset with adverse features, poor failure-free survival and outcome with conventional therapyJason Westin, Peter McLaughlin
Leukemia & Lymphoma|October 30, 2009
Interferon: does it still have a role in the 21st century?Peter McLaughlin, Stefano Sacchi
Leukemia & Lymphoma|March 29, 2011
The pharmacokinetic fate of an immunotoxin: HAMA, HARA, ding, ding, dongMichael Rosenblum, Peter McLaughlin
Leukemia & Lymphoma|February 24, 2009
Seeking wisdom from the SeerPeter McLaughlin, Jonathan W Friedberg
Cardiology Clinics|October 10, 2002
How congenital heart disease originates in fetal lifeRuth Collins-Nakai, Peter McLaughlin
Leukemia & Lymphoma|September 24, 2015
Stage I-II follicular lymphoma: an endangered species?Peter McLaughlin, John F Seymour
Leukemia & Lymphoma|May 3, 2008
R-DHAP: a good small step, but not the journey's endPeter McLaughlin, Julie M Vose
Cardiology Clinics|November 14, 2006
The role of cardiac catheterization in adult congenital heart diseasePeter McLaughlin, Lee Benson, Eric Horlick
Leukemia & Lymphoma|August 3, 2013
Chemoimmunotherapy with fludarabine, cytoxan and rituximab regimen: to use, not to use, or give it as "FCR-LITE"?Tamar Tadmor, Peter McLaughlin, Aaron Polliack
Pageof 12